Catalent's Stock Tumbles on Reduced Revenue Forecast and Delayed Earnings.
TL;DR
Contract drug manufacturer Catalent has delayed its Q3 earnings report and expects to "significantly reduce" guidance for the fiscal year, causing its stock to drop.
Topics:business#business#catalent#contract-drug-manufacturer#earnings-report#fiscal-year#profit-warning
- Catalent Stock Sinks. It Expects to 'Significantly Reduce' Guidance. Barron's
- Catalent says to cut 2023 revenue forecast, delays Q3 results Yahoo Finance
- Catalent Stock Plunges After Delayed Earnings, Guidance Cut The Wall Street Journal
- Catalent shares tank on warning of $400 mln cut to annual revenue forecast Reuters
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Barron's